Similar articles

• A double-blind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. II. Biochemical findings.

  Aberg-Wistedt A, Ross SB, Jostell KG, Sjöquist B. Aberg-Wistedt A, et al. Acta Psychiatr Scand. 1982 Jul;66(1):66-82. doi: 10.1111/j.1600-0447.1982.tb00915.x. Acta Psychiatr Scand. 1982. PMID: 6181652
• Platelet serotonin uptake inhibition as a basis for monitoring antidepressant drug treatment.

  Lingjaerde O. Lingjaerde O. J Clin Psychopharmacol. 1984 Apr;4(2):76-81. J Clin Psychopharmacol. 1984. PMID: 6231316 Clinical Trial.
• Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites.

  Potter WZ, Scheinin M, Golden RN, Rudorfer MV, Cowdry RW, Calil HM, Ross RJ, Linnoila M. Potter WZ, et al. Arch Gen Psychiatry. 1985 Dec;42(12):1171-7. doi: 10.1001/archpsyc.1985.01790350045009. Arch Gen Psychiatry. 1985. PMID: 2416297 Clinical Trial.
• CSF monoamine metabolites, depression, and suicide.

  Asberg M, Bertilsson L, Mårtensson B. Asberg M, et al. Adv Biochem Psychopharmacol. 1984;39:87-97. Adv Biochem Psychopharmacol. 1984. PMID: 6205566 Review. No abstract available.
• Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease.

  Mayeux R. Mayeux R. Neurol Clin. 1984 Aug;2(3):527-40. Neurol Clin. 1984. PMID: 6085395 Review.